• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • BioAsia 2023 to be held in February 24-26 in Telangana, India
  • Praj Industries and ESIIC partner to further bioeconomy in Egypt
  • Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian?
  • Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE
  • Event: Australia’s biggest week in biotech kicks off in Perth
  • $3 trillion growth reported for biotech sector in USA
  • Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect”
  • Vaccination, Rising Deaths, And The False Narrative
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    July 26, 2022

    We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO

    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

    January 24, 2022

    Interview: Prof Kailash Chander Bansal, Secretary, National Academy of Agricultural Sciences (NAAS), India

  • Issues
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»Articles»India’s Bharat Biotech Covaxin shows best results among three COVID-19 vaccines present worldwide: What else WHO needs for EUA?

India’s Bharat Biotech Covaxin shows best results among three COVID-19 vaccines present worldwide: What else WHO needs for EUA?

0
By Biotech Express on July 19, 2021 Articles, Articles- Editorials, SARS- CoV2 & COVID-19 Updates

The Indian company Bharat Biotech (BB) on 3rd July 2021, released a press release about the final analysis for COVAXIN efficacy as part of phase 3 clinical trials after publishing preprint data on medRxiv. Here in this article we are comparing Phase 3 results of world’s 3 most popular COVID vaccines that are in vaccination drives around the world. 2 out of 3 got huge funding from international organizations for R&D and manufacturing and already have won Emergency Use Approval from WHO and FDA but Covaxin has to wait despite its high effectiveness and safety profile because it is from third world country.

It has been discussed in other articles of this issue that how the provenience of vaccine plays a role in approval through WHO and FDA. We have also seen in other articles from Biotech Express that how in COVID pandemics, the FDA and WHO have had become puppets of high impact journal like the Lancet and NEJM and changed their decisions toward COVID treatment in alternate manner when these studies were published and then retracted.

According to WHO and other health organizations, the vaccines are the most effective tool against the deadly coronavirus that is making fatalities around the world. From the very starting the world is trying to make a vaccine that can address various concerns regarding safety and efficacy but all the drugs and vaccines that are approved till now have come under scrutiny because they were contradicted by experts, some of them even banned for use and guidance was provided to not use them, the greatest example is HCQ. All have been objected except the Covaxin of Bharat Biotech which has not shown any severe side effects or deaths after vaccination.

We have seen the present condition of vaccine hesitancy and discussed separately in an article in this issue, that how despite having so many vaccines people are not willing to take them because they are not sure of trial results. Using a table we have articulated points that are destined to understand doubts about vaccine hesitancy in each vaccine and to check which vaccine can remove hesitancy from the minds of people all around the world.

Since the start of pandemic we have seen that every Chinese product has been questioned and subsequently rejected given the quality of products, for example the diagnostic kits which were rejected by several nations including India and Italy. Keeping this in mind the article has not included Chinese Sinovac’s CoronaVac, because its efficacy has been questioned recently in Indonesian population.

In current times, the most intriguing questions about COVID vaccine include safety, efficacy, effectiveness against variants, pregnancy, symptomatic efficacy, neutralization response etc. so we will discuss these points and try to find out the best vaccine.

Now coming to the most abundant vaccines that have been inoculated to masses till now are of Astrazeneca (ChAdOx1 nCoV-19), Pfizer (mRNA-1273) and Bharat Biotech (Covaxin). The former two released phase 3 results much earlier than latter.

To start with, though Astrazeneca has published results but still it is interim analysis whereas other two have published final results. None of the vaccine has considered vast racial and ethnic diversity.

Most importantly in current scenario after emerging variants, Covaxin group has studied the effects on variants specially the delta variant while other two have reported no studies in this respect. Pfizer currently asked WHO for booster dose for delta variant but Covaxin is ready for the same purpose without any additional cost and efforts.

Cost is an important factor to inoculate whole population, Astrazeneca’s vaccine in this respect can be a great worry as it requires booster dose for complete effect while other two do so in doses as described in trial results. Also Covaxin dose is very low so the manufacturing cost, and at the same time because the dose is low the chances of allergic reactions or side effects are also negligible.

The storage of vaccine is great for COVAXIN and Astrazeneca but because the conditions are stringent for Pfizer, the cost of maintaining the lots and the chances of wastage are also high.

Vaccine manufacturing lots consistency was questioned worldwide after it was found that Pfizer’s mRNA concentration was different in the supplied vaccine as compared to trial vaccine, as per the leaked documents analyzed by BMJ. Covaxin is the only vaccine that has considered manufacturing lot consistency and so each vial has the same material and as much safe as the material used in trials.

When we talk about the vaccine trial conditions, the COVAXIN has recruited largest number of participants as well as done studies to the longest time to see the post vaccination effects. It also considered pregnancy related studies in females whereas other two did not. Covaxin and Pfizer also considered subjects at risk whereas data for the same is not available for Astrazeneca’s vaccine, lack of this data does not tell us that how this vaccine works against serious cases.

To study the effect of vaccine it is important to know how many subjects still got the disease after the therapy i.e the safety of vaccine. In Covaxin the number of subjects who got symptomatic after vaccine is far less than the other two in both patient group as well as the placebo. The higher number of symptomatic cases in placebo group in comparison to patient group after vaccination, showed that vaccine prevented the COVID symptoms.

The overall Efficacy of Covaxin lies between Astrazeneca’s and Pfizer vaccines but the efficacy in severe cases which is real efficacy of vaccine is shown only in Covaxin and not other two, it is 93.4% in Covaxin group and thus it can prevent serious COVID cases.

What will happen to future immunity against virus, it is not sure in Astrazeneca’s and Pfizer vaccines because both other two have not done studies to see the effect whereas Covaxin has shown that it produces neutralizing antibodies that provide long term immunity against virus so there is no need of further expenses to get booster dose in future.

Serious adverse events were also reported in Astra and Pfizer vaccine like Anaphylaxis, Transverse Myelitis Myocardial Infarction, Cholecystitis, Nephrolithiasis, Bell’s Palsy that if not considered for further studies can lead to wipe out of huge population or long term effects on health. Covaxin in this respect has been proved as safe because it reported no side effects after vaccination.

 

Conclusion:

From the above discussion it is easy to conclude that though Covaxin was little late in doing studies and producing little doses than others but it has come out as the safest and most effective vaccine on several parameters that were not considered by other vaccine producers. It is an answer to people who are showing vaccine hesitancy. It is manufactured in safe environment and so the chances of contamination are negligible. If we set aside the politics, the WHO should approve this product for the benefit of human race and international funding agencies should fund Bharat Biotech to increase the manufacturing capacity of COVAXIN as the delta variant is again emerging and the cases are rising in USA and other countries. We have seen that none of the vaccine is effective against delta variant and thus Covaxin is the only choice the world has to save its people.

Published in July 2021 Issue

References:

1. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext
2. https://www.nejm.org/doi/full/10.1056/nejmoa2035389
3. https://www.medrxiv.org/content/10.1101/2021.06.30.21259439v1
4. https://www.gavi.org/vaccineswork/indias-covaxin-vaccine-shows-high-efficacy-against-covid-19-infections-phase-3

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian?

Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE

Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect”

Leave A Reply Cancel Reply

Current Issue – October 2022
Upcoming Event

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • BioAsia 2023 to be held in February 24-26 in Telangana, India January 10, 2023
  • Praj Industries and ESIIC partner to further bioeconomy in Egypt November 10, 2022
  • Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian? November 1, 2022
  • Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE October 31, 2022
  • Event: Australia’s biggest week in biotech kicks off in Perth October 26, 2022
  • $3 trillion growth reported for biotech sector in USA October 25, 2022
  • Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect” September 21, 2022
  • Vaccination, Rising Deaths, And The False Narrative September 20, 2022
  • Guestorial: Genome Mapping Techniques and its Application in Aquaculture September 19, 2022
  • Bombay HC Issues Notice To Bill Gates, Serum Institute, DGCI, Others Over Plea On Alleged ‘Vaccine Death’ September 5, 2022
  • Deaths due Covid-19 vaccines should be compensated by vaccine makers: Expert hope on Kerala HC remark August 21, 2022
  • Maker of Dolo-650, pandemic’s ‘magic pill’, faces income tax searches and PIL petitions August 20, 2022
  • Anthony Fauci, Controversial US Top-doc FINALLY, To Retire By Year-end August 20, 2022
  • SII’s Cervevac: The new DCGI approved vaccine without published clinical trial results August 20, 2022
  • Pitch your Start-up to National/International Venture Capitalists – first ever opportunity provided to Bio-Start-ups by FABA August 19, 2022
  • India’s Clinical Trial Registry might disappear soon and so the history of pharma record August 19, 2022
  • Nearly Half of Pregnant Women in Pfizer Trial Miscarried August 10, 2022
  • Researchers develop Cellulose shoes made by bacteria August 9, 2022
  • Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility August 5, 2022
  • CBI Arrests of CDSCO officials, a Biocon official & Intermediaries in an alleged bribery case exposed Corruption in Govt and Pharma sector July 27, 2022
  • We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO July 26, 2022
  • EVENT HIGHLIGHTS: Genome editing as a novel technology for sustainable development July 24, 2022
  • US Military Doctor Testifies under Oath That She Was ORDERED To ‘Cover up’ COVID Vaccine Injuries July 24, 2022
  • Climatic Effect on Marine Biodiversity and their impact on coral reefs July 23, 2022
  • Highlights of India’s first Biotech startup Expo June 13, 2022
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity June 6, 2022
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds May 30, 2022
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft May 26, 2022
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak May 25, 2022
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid May 25, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • Biotech News
  • Biotech News – Featured
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.